{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:28Z","timestamp":1772120008358,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Harbin Medical University Cancer Hospital Haiyan Research Foundation","award":["JJZD2022-01"],"award-info":[{"award-number":["JJZD2022-01"]}]},{"name":"the Harbin Medical University Cancer Hospital Haiyan Research Foundation","award":["JJZD2022-01"],"award-info":[{"award-number":["JJZD2022-01"]}]},{"name":"the Harbin Medical University Cancer Hospital Haiyan Research Foundation","award":["JJZD2022-01"],"award-info":[{"award-number":["JJZD2022-01"]}]},{"name":"the Harbin Medical University Cancer Hospital Haiyan Research Foundation","award":["JJZD2022-01"],"award-info":[{"award-number":["JJZD2022-01"]}]},{"name":"the Harbin Medical University Cancer Hospital Haiyan Research Foundation","award":["JJZD2022-01"],"award-info":[{"award-number":["JJZD2022-01"]}]},{"name":"the Harbin Medical University Cancer Hospital Haiyan Research Foundation","award":["JJZD2022-01"],"award-info":[{"award-number":["JJZD2022-01"]}]},{"name":"the Harbin Medical University Cancer Hospital Haiyan Research Foundation","award":["JJZD2022-01"],"award-info":[{"award-number":["JJZD2022-01"]}]},{"name":"the Harbin Medical University Cancer Hospital Haiyan Research Foundation","award":["JJZD2022-01"],"award-info":[{"award-number":["JJZD2022-01"]}]},{"name":"the Harbin Medical University Cancer Hospital Haiyan Research Foundation","award":["JJZD2022-01"],"award-info":[{"award-number":["JJZD2022-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03106-4","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T07:50:00Z","timestamp":1762588200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["T\u03b24\u201317 peptide enhances the chemo-sensitivity of ovarian cancer cells to DDP by affecting NF-\u03baB signaling pathway"],"prefix":"10.1007","volume":"42","author":[{"given":"Ling","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peihua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lichen","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"issue":"1","key":"3106_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/cncr.22749","volume":"110","author":"M Markman","year":"2007","unstructured":"Markman M. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;110(1):226\u20137. https:\/\/doi.org\/10.1002\/cncr.22749.","journal-title":"Cancer"},{"issue":"9","key":"3106_CR2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-8053","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ren S, Jiang W, Lu J, Zhang X, Li X, et al. CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels. Ann Transl Med. 2021;9(9):788. https:\/\/doi.org\/10.21037\/atm-20-8053.","journal-title":"Ann Transl Med"},{"issue":"3","key":"3106_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1006\/gyno.1998.5145","volume":"72","author":"RE Bristow","year":"1999","unstructured":"Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):278\u201387. https:\/\/doi.org\/10.1006\/gyno.1998.5145.","journal-title":"Gynecol Oncol"},{"key":"3106_CR4","doi-asserted-by":"publisher","first-page":"iv259","DOI":"10.1093\/annonc\/mdy157","volume":"29","author":"J Ledermann","year":"2018","unstructured":"Ledermann J, Raja F, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv259. https:\/\/doi.org\/10.1093\/annonc\/mdy157.","journal-title":"Ann Oncol"},{"key":"3106_CR5","doi-asserted-by":"publisher","first-page":"113345DOI","DOI":"10.1016\/j.biopha.2022.113345","volume":"153","author":"R Bhattacharjee","year":"2022","unstructured":"Bhattacharjee R, Dey T, Kumar L, Kar S, Sarkar R, Ghorai M, et al. Cell Landscaping Cisplatin Resist Cerv Cancer Biomed Pharmacother. 2022;153:113345DOI. https:\/\/doi.org\/10.1016\/j.biopha.2022.113345.","journal-title":"Cell Landscaping Cisplatin Resist Cerv Cancer Biomed Pharmacother"},{"key":"3106_CR6","doi-asserted-by":"publisher","unstructured":"Lugones Y, Loren P, Salazar L. Cisplatin Resistance: Genetic Epigenetic Factors Involved Biomolecules. 2022;12(10). https:\/\/doi.org\/10.3390\/biom12101365.","DOI":"10.3390\/biom12101365"},{"issue":"4","key":"3106_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3892\/ol.2023.13759","volume":"25","author":"C De Souza Dutra","year":"2023","unstructured":"De Souza Dutra C, Da Cruz Schafhauser D, Hentz M, Mayer N, Pinheiro R, Baierle G, et al. Urinary endogenous peptides as biomarkers for prostate cancer. Oncol Lett. 2023;25(4):173. https:\/\/doi.org\/10.3892\/ol.2023.13759.","journal-title":"Oncol Lett"},{"key":"3106_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2020.105687","volume":"120","author":"X Li","year":"2020","unstructured":"Li X, Li J, Zhang B, Gu Y, Li Q, Gu G, et al. Comparative peptidome profiling reveals critical roles for peptides in the pathology of pancreatic cancer. Int J Biochem Cell Biol. 2020;120:105687. https:\/\/doi.org\/10.1016\/j.biocel.2020.105687.","journal-title":"Int J Biochem Cell Biol"},{"key":"3106_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121975","volume":"293","author":"Y Hao","year":"2023","unstructured":"Hao Y, Chen Y, He X, Han R, Yang C, Liu T, et al. RGD peptide modified platinum nanozyme co-loaded glutathione-responsive prodrug nanoparticles for enhanced chemo-photodynamic bladder cancer therapy. Biomaterials. 2023;293:121975. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121975.","journal-title":"Biomaterials"},{"issue":"3","key":"3106_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1568009619666191111141032","volume":"20","author":"C Ng","year":"2020","unstructured":"Ng C, Lee S. The potential use of anticancer peptides (ACPs) in the treatment of hepatocellular carcinoma. Curr Cancer Drug Targets. 2020;20(3):187\u201396. https:\/\/doi.org\/10.2174\/1568009619666191111141032.","journal-title":"Curr Cancer Drug Targets"},{"key":"3106_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27041426","author":"S Maijaroen","year":"2022","unstructured":"Maijaroen S, Klaynongsruang S, Roytrakul S, Konkchaiyaphum M, Taemaitree L, Jangpromma N. An integrated proteomics and bioinformatics analysis of the anticancer properties of RT2 antimicrobial peptide on human colon cancer (Caco-2) cells. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27041426.","journal-title":"Molecules"},{"issue":"4","key":"3106_CR12","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3892\/ijo.2016.3390","volume":"48","author":"M Zhao","year":"2016","unstructured":"Zhao M, Wei C, Yang X, Zhou J, Wang J, Gu F, et al. The milk-derived hexapeptide PGPIPN inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes. Int J Oncol. 2016;48(4):1721\u20139. https:\/\/doi.org\/10.3892\/ijo.2016.3390.","journal-title":"Int J Oncol"},{"issue":"1","key":"3106_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00280-004-0929-4","volume":"56","author":"J Jaglowski","year":"2005","unstructured":"Jaglowski J, Zagon I, Stack B, Verderame M, Leure-duPree A, Manning J, et al. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2005;56(1):97\u2013104. https:\/\/doi.org\/10.1007\/s00280-004-0929-4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3106_CR14","doi-asserted-by":"publisher","unstructured":"Hilchie A, Sharon A, Haney E, Hoskin D, Bally M, Franco O et al. 2016.Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma.https:\/\/doi.org\/10.1016\/j.bbamem.2016.09.021","DOI":"10.1016\/j.bbamem.2016.09.021"},{"issue":"7","key":"3106_CR15","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.molonc.2015.04.005","volume":"9","author":"B Cheung","year":"2015","unstructured":"Cheung B, Tan O, Koach J, Liu B, Shum M, Carter D, et al. Thymosin-\u03b24 is a determinant of drug sensitivity for fenretinide and vorinostat combination therapy in neuroblastoma. Mol Oncol. 2015;9(7):1484\u2013500. https:\/\/doi.org\/10.1016\/j.molonc.2015.04.005.","journal-title":"Mol Oncol"},{"key":"3106_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109785","volume":"116","author":"A Naeem","year":"2023","unstructured":"Naeem A, Knoer G, Laura Avantaggiati M, Rodriguez O, Albanese C. Provocative non-canonical roles of p53 and AKT signaling: a role for thymosin \u03b24 in Medulloblastoma. Int Immunopharmacol. 2023;116:109785. https:\/\/doi.org\/10.1016\/j.intimp.2023.109785.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"3106_CR17","doi-asserted-by":"publisher","first-page":"e12058","DOI":"10.1002\/ccs3.12058","volume":"19","author":"NY Li","year":"2025","unstructured":"Li NY, Guo P, Wang L, Cui H, Teng B, Su L, Yajuan. The small molecule peptide ANXA114-26 inhibits ovarian cancer cell proliferation and reverses cisplatin resistance by binding to the formyl peptide receptors receptor. J Cell Communication Signal. 2025;19(11):e12058. https:\/\/doi.org\/10.1002\/ccs3.12058.","journal-title":"J Cell Communication Signal"},{"issue":"3","key":"3106_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/jso.27125","volume":"127","author":"A Ayhan","year":"2023","unstructured":"Ayhan A, Akilli H, Abasiyanik M, Taskiran C. Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: when, and for whom? J Surg Oncol. 2023;127(3):457\u201364. https:\/\/doi.org\/10.1002\/jso.27125.","journal-title":"J Surg Oncol"},{"issue":"1","key":"3106_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s41021-021-00192-4","volume":"43","author":"A Zangouei","year":"2021","unstructured":"Zangouei A, Moghbeli M. Micrornas as the critical regulators of cisplatin resistance in gastric tumor cells. Genes Environ. 2021;43(1):21. https:\/\/doi.org\/10.1186\/s41021-021-00192-4.","journal-title":"Genes Environ"},{"issue":"10","key":"3106_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.15252\/emmm.201607012","volume":"9","author":"A Dall\u2019Acqua","year":"2017","unstructured":"Dall\u2019Acqua A, Sonego M, Pellizzari I, Pellarin I, Canzonieri V, D\u2019Andrea S, et al. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. Embo Mol Med. 2017;9(10):1415\u201333. https:\/\/doi.org\/10.15252\/emmm.201607012.","journal-title":"Embo Mol Med"},{"key":"3106_CR21","doi-asserted-by":"publisher","unstructured":"Ghose A, Gullapalli S, Chohan N, Bolina A, Moschetta M, Rassy E, et al. Appl Proteom Ovarian Cancer: Dawn New Era Proteomes. 2022;10(2). https:\/\/doi.org\/10.3390\/proteomes10020016.","DOI":"10.3390\/proteomes10020016"},{"issue":"5","key":"3106_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1586\/14737159.7.5.605","volume":"7","author":"H Tammen","year":"2007","unstructured":"Tammen H, Peck A, Budde P, Zucht H. Peptidomics analysis of human blood specimens for biomarker discovery. Expert Rev Mol Diagn. 2007;7(5):605\u201313. https:\/\/doi.org\/10.1586\/14737159.7.5.605.","journal-title":"Expert Rev Mol Diagn"},{"key":"3106_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1135523","volume":"13","author":"L Guo","year":"2023","unstructured":"Guo L, Wang J, Li N, Cui J, Su Y. Peptides for diagnosis and treatment of ovarian cancer. Front Oncol. 2023;13:1135523. https:\/\/doi.org\/10.3389\/fonc.2023.1135523.","journal-title":"Front Oncol"},{"issue":"7","key":"3106_CR24","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1158\/1535-7163.mct-21-0848","volume":"21","author":"X Pan","year":"2022","unstructured":"Pan X, Geng Z, Li J, Li X, Zhang M, Wang X, et al. Peptide PDHPS1 inhibits ovarian cancer growth through disrupting YAP signaling. Mol Cancer Ther. 2022;21(7):1160\u201370. https:\/\/doi.org\/10.1158\/1535-7163.mct-21-0848.","journal-title":"Mol Cancer Ther"},{"issue":"43","key":"3106_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405620","volume":"11","author":"Y Yin","year":"2024","unstructured":"Yin Y, Li Y, Ma B, et al. Mitochondrial-derived peptide MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination. Adv Sci. 2024;11(43):e2405620. https:\/\/doi.org\/10.1002\/advs.202405620.","journal-title":"Adv Sci"},{"issue":"8","key":"3106_CR26","doi-asserted-by":"publisher","first-page":"13632","DOI":"10.18632\/oncotarget.14621","volume":"8","author":"Y Kim","year":"2017","unstructured":"Kim Y, Kim H, Park D, Lee H, Lee Y, Choe J, et al. The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3\u03b2 and decreasing the expression of cyclinD1. Oncotarget. 2017;8(8):13632\u201351. https:\/\/doi.org\/10.18632\/oncotarget.14621.","journal-title":"Oncotarget"},{"key":"3106_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1444973","volume":"15","author":"A Lacroix","year":"2024","unstructured":"Lacroix A, Farhat R, Robert A, et al. The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models. Front Pharmacol. 2024;15:1444973. https:\/\/doi.org\/10.3389\/fphar.2024.1444973.","journal-title":"Front Pharmacol"},{"key":"3106_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1541-7786.MCR-13-0542","volume":"12","author":"AS Farrell","year":"2014","unstructured":"Farrell AS, Allen-Petersen B, Daniel CJ, Wang X, Wang Z, Rodriguez S, et al. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res. 2014;12:924\u201339. https:\/\/doi.org\/10.1158\/1541-7786.MCR-13-0542.","journal-title":"Mol Cancer Res"},{"key":"3106_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050901","author":"KLM Boylan","year":"2025","unstructured":"Boylan KLM, Walz C, Schefter AM, et al. A peptide derived from Nectin-4 increases Cisplatin cytotoxicity in cell lines and cells from ovarian cancer patients\u2019 ascites. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17050901.","journal-title":"Cancers (Basel)"},{"key":"3106_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1652166","volume":"16","author":"IH Han","year":"2025","unstructured":"Han IH, Choi I, Kim S, Kwon M, Choi H, Bae H. Immunomodulatory peptide-drug conjugate MEL-dKLA suppresses progression of prostate cancer by eliminating M2-like tumor-associated macrophages. Front Immunol. 2025;16:1652166. https:\/\/doi.org\/10.3389\/fimmu.2025.1652166.","journal-title":"Front Immunol"},{"issue":"1","key":"3106_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01719-9","volume":"22","author":"R Song","year":"2023","unstructured":"Song R, Ma S, Xu J, et al. A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR. Mol Cancer. 2023;22(1):16. https:\/\/doi.org\/10.1186\/s12943-023-01719-9.","journal-title":"Mol Cancer"},{"issue":"6","key":"3106_CR32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.hoc.2018.07.007","volume":"32","author":"AE Freimund","year":"2018","unstructured":"Freimund AE, Beach JA, Christie EL, Bowtell DDL. Mechanisms of drug resistance in high-grade serous ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):983\u201396. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.007.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3106_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113951","volume":"156","author":"C Guan","year":"2022","unstructured":"Guan C, Zhou X, Li H, Ma X, Zhuang J. NF-\u03baB inhibitors gifted by nature: the anticancer promise of polyphenol compounds. Biomed Pharmacother. 2022;156:113951. https:\/\/doi.org\/10.1016\/j.biopha.2022.113951.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"3106_CR34","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41416-020-0783-0","volume":"122","author":"Z Yuan","year":"2020","unstructured":"Yuan Z, Liang X, Zhan Y, Wang Z, Xu J, Qiu Y, et al. Targeting CD133 reverses drug-resistance via the AKT\/NF-\u03baB\/MDR1 pathway in colorectal cancer. Br J Cancer. 2020;122(9):1342\u201353. https:\/\/doi.org\/10.1038\/s41416-020-0783-0.","journal-title":"Br J Cancer"},{"issue":"3","key":"3106_CR35","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/cam4.1971","volume":"8","author":"C Tan","year":"2019","unstructured":"Tan C, Liu L, Liu X, Qi L, Wang W, Zhao G, et al. Activation of PTGS2\/NF-\u03bab signaling pathway enhances radiation resistance of glioma. Cancer Med. 2019;8(3):1175\u201385. https:\/\/doi.org\/10.1002\/cam4.1971.","journal-title":"Cancer Med"},{"issue":"9","key":"3106_CR36","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/cas.12478","volume":"105","author":"H Yan","year":"2014","unstructured":"Yan H, Huang X, Ke S, Jiang Y, Zhang Y, Wang Y, et al. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated\/NF-kappaB pathway activation. Cancer Sci. 2014;105(9):1220\u20137. https:\/\/doi.org\/10.1111\/cas.12478.","journal-title":"Cancer Sci"},{"issue":"5","key":"3106_CR37","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/cns.13591","volume":"27","author":"YH Hu","year":"2021","unstructured":"Hu YH, Jiao BH, Wang CY, Wu JL. Regulation of Temozolomide resistance in glioma cells via the RIP2\/NF-kappaB\/MGMT pathway. Cns Neurosci Ther. 2021;27(5):552\u201363. https:\/\/doi.org\/10.1111\/cns.13591.","journal-title":"Cns Neurosci Ther"},{"issue":"3","key":"3106_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-020-04215-9","volume":"87","author":"Y Liu","year":"2021","unstructured":"Liu Y, Jia Y, Liu S, Ma J. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-\u03baB pathway. Cancer Chemother Pharmacol. 2021;87(3):405\u201314. https:\/\/doi.org\/10.1007\/s00280-020-04215-9.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3106_CR39","doi-asserted-by":"publisher","first-page":"8241","DOI":"10.2147\/CMAR.S265531","volume":"12","author":"Y Kan","year":"2020","unstructured":"Kan Y, Liu J, Li F. High expression of nuclear transcription factor-\u03bab is associated with cisplatin resistance and prognosis for ovarian cancer. Cancer Manag Res. 2020;12:8241\u201352. https:\/\/doi.org\/10.2147\/CMAR.S265531.","journal-title":"Cancer Manag Res"},{"issue":"7","key":"3106_CR40","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/cas.13276","volume":"108","author":"X Yan","year":"2017","unstructured":"Yan X, Zhang Y, Zhang J, Zhang L, Liu Y, Wu Y, et al. P62\/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-\u03baB pathway in human ovarian cancer cells. Cancer Sci. 2017;108(7):1405\u201313. https:\/\/doi.org\/10.1111\/cas.13276.","journal-title":"Cancer Sci"},{"key":"3106_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123784","author":"A Noonan","year":"2020","unstructured":"Noonan A, Cousins A, Anderson D, Zeligs K, Bunch K, Hernandez L, et al. Matrix drug screen identifies synergistic drug combinations to augment SMAC mimetic activity in ovarian cancer. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12123784.","journal-title":"Cancers"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03106-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03106-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03106-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T03:43:53Z","timestamp":1763783033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03106-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3106"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03106-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6951674\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"This study involved the secondary use of clinically archived serum specimens; exemption from informed consent was approved by the Ethics Committee of Harbin Medical University Cancer Hospital.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate statement"}},{"value":"Due to limited experimental resources, some assays could not be undertaken; we will complete the necessary in vivo studies once our research facilities are upgraded.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Limitations and future directions"}}],"article-number":"541"}}